Nixodine-S™ Study Signals a Potential Breakthrough Beyond Nicotine

Data ReadoutpositiveNixodine-S™Positive

AI Analysis

Summary

Bonguard Naturals announced study results for Nixodine-S™, a patented nicotine alternative that maintained receptor activity associated with satisfaction while demonstrating improved in vitro cytotoxicity profile compared to nicotine.

Outcome Details

Patented alternative preserved nicotine-like activity at key satisfaction-related receptors while producing markedly more favorable in vitro cytotoxicity result than nicotine

Importance:4/10

Sentiment:

0.70

nicotine alternativein vitro studycytotoxicityreceptor activity

Read the original article

Published by PR Newswire Biotech on August 24, 2026 5:53 PM

Read Original